Related Experiment Video
Updated: Jul 4, 2026
06:54
A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
Published on: November 15, 2024
Dimethylcelecoxib inhibits prostaglandin E2 production
Ivonne Wobst1, Susanne Schiffmann, Kerstin Birod
1pharmazentrum frankfurt/ZAFES, Institute for Clinical Pharmacology, Johann Wolfgang Goethe-University Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany.
Biochemical Pharmacology
|May 30, 2008
Summary
Dimethylcelecoxib (DMC) inhibits prostaglandin E2 (PGE2) production by affecting microsomal prostaglandin E synthase-1 (mPGES-1). Despite its intended use as a control, DMC impacts prostaglandin synthesis, making it unsuitable for COX-independent research.
Area of Science:
- Biochemistry
- Pharmacology
- Cancer Research
Background:
- Celecoxib derivatives are used to study COX-dependent and independent effects.
- Dimethylcelecoxib (DMC) was developed to have no COX inhibitory activity.
- Ensuring DMC does not affect prostaglandin production is crucial for its use as a control.
Purpose of the Study:
- To investigate the effects of DMC on prostaglandin E2 (PGE2) production.
- To determine the mechanism by which DMC influences PGE2 synthesis.
- To evaluate the suitability of DMC as a COX-independent control substance.
Main Methods:
- In vitro assays measuring PGE2 production in cancer cell lines.
- Cell-free assays to assess inhibition of microsomal prostaglandin E synthase-1 (mPGES-1).
- Analysis of COX-1, COX-2, cPGES, and mPGES-2 expression levels.
- Cell proliferation assays (WST-1) with and without external PGE2 stimulation.
Main Results:
- DMC inhibits PGE2 production in cancer cell lines at low micromolar concentrations.
- DMC inhibits mPGES-1 activity in a cell-free assay and prevents its upregulation.
- DMC does not affect the expression of COX-1, COX-2, cPGES, or mPGES-2.
- DMC's anti-proliferative effects are independent of PGE2 inhibition.
Conclusions:
- DMC inhibits PGE2 production through mechanisms at least partly involving mPGES-1.
- DMC's impact on mPGES-1 is not fully explained by cell-free assay results.
- DMC is not a suitable control substance for research requiring non-prostaglandin-inhibiting properties.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...